Delayed and limited administration of the JAKinib tofacitinib mitigates chronic DSS-induced colitis
Open Access
- 19 May 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14
Abstract
In inflammatory bowel disease, dysregulated T cells express pro-inflammatory cytokines. Using a chronic azoxymethane (AOM)/dextran sulfate sodium (DSS)-induced colitis model resembling ulcerative colitis, we evaluated whether and when treatment with the Janus kinase (JAK) inhibitor tofacitinib could be curative. Comparing the treatment with two and three cycles of tofacitinib medication in drinking water – intermittently with DSS induction – revealed that two cycles were not only sufficient but also superior over the 3-x regimen. The two cycles of the 2-x protocol paralleled the second and third cycles of the longer protocol. T cells were less able to express interferon gamma (IFN-γ) and the serum levels of IFN-γ, interleukin (IL)-2, IL-6, IL-17, and tumor necrosis factor (TNF) were significantly reduced in sera, while those of IL-10 and IL-22 increased under the 2-x protocol. Likewise, the frequency and effector phenotype of regulatory T cells (Tregs) increased. This was accompanied by normal weight gain, controlled clinical scores, and restored stool consistency. The general and histologic appearance of the colons revealed healing and tissue intactness. Importantly, two phases of tofacitinib medication completely prevented AOM-incited pseudopolyps and the hyper-proliferation of epithelia, which was in contrast to the 3-x regimen. This implies that the initial IBD-induced cytokine expression is not necessarily harmful as long as inflammatory signaling can later be suppressed and that time-restricted treatment allows for anti-inflammatory and tissue-healing cytokine activities.Keywords
Funding Information
- Pfizer (WI214096)
- Deutsche Forschungsgemeinschaft (324392634 - TRR 221)
- Wilhelm Sander-Stiftung
- Fritz Thyssen Stiftung
This publication has 60 references indexed in Scilit:
- TNFR2 Expression on CD25hiFOXP3+ T Cells Induced upon TCR Stimulation of CD4 T Cells Identifies Maximal Cytokine-Producing EffectorsFrontiers in Immunology, 2013
- NFATc1/αA: The other Face of NFAT Factors in LymphocytesCell Communication and Signaling, 2012
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)The Journal of Immunology, 2011
- Intestinal microbiota in inflammatory bowel disease: Friend of foe?World Journal of Gastroenterology, 2011
- The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studiesJournal of Carcinogenesis, 2011
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritisJournal of Inflammation, 2010
- Inflammatory Bowel DiseaseNew England Journal of Medicine, 2009
- Janus kinases in immune cell signalingImmunological Reviews, 2009
- IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitisJournal of Clinical Investigation, 2008
- Epithelial Cell Adhesion MoleculeThe American Journal of Pathology, 2007